enzaludamide

POSITIVE RESULTS FROM PHASE 3 ARCHES TRIAL OF XTANDI® (ENZALUTAMIDE) IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

It was announced today that the Phase 3 ARCHES trial which evaluated XTANDI (enzalutamide) along with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone. 

The Synergy between Xtandi and Zytiga with ADT – Is it Important to Continue Taking ADT Along with Xtandi and Zytiga?

Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?

Tripolide Is A Potential Advanced Prostate Cancer Treatment - On The Horizon

There is a great need to develop new treatments for advanced prostate cancer.  Tripolide, derived from a Chinese herb, shows the potential to enhance Xtandi and combat the natural resistance that develops over time.